Technical Analysis for OTIC - Otonomy, Inc.

Grade Last Price % Change Price Change
grade F 2.03 0.50% 0.01
OTIC closed up 0.5 percent on Wednesday, January 16, 2019, on 17 percent of normal volume. The price action carved out a bearish shooting star candlestick pattern. That may indicate a downside reversal. Look for price to trade beneath the low of the shooting star for confirmation. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Up
See historical OTIC trend table...

Date Alert Name Type % Chg
Jan 16 Shooting Star Candlestick Bearish 0.00%
Jan 16 Lizard Bearish Bearish Day Trade Setup 0.00%
Jan 16 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Jan 16 Weak + Overbought Other 0.00%
Jan 16 Wide Bands Range Expansion 0.00%
Jan 16 Weak, Overbought and Reversal Signs Reversal 0.00%
Jan 16 Overbought Stochastic Strength 0.00%
Jan 16 Up 3 Days in a Row Strength 0.00%
Jan 15 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.50%
Jan 15 Spinning Top Other 0.50%

Older signals for OTIC ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Otonomy, Inc. develops and commercializes therapeutics for the treatment of ear diseases and disorders primarily in the United States. Its lead product candidate is AuriPro, a sustained-exposure antibiotic, which is in Phase III clinical trials to treat pediatric patients with middle ear effusion at the time of tympanostomy tube placement surgery. The company also develops OTO-104, a sustained-exposure formulation of the steroid dexamethasone that is in a Phase IIb clinical trial for the treatment of patients with Ménière's disease; and OTO-311, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in preclinical development as a potential treatment for tinnitus. Otonomy, Inc. was founded in 2008 and is headquartered in San Diego, California.
Is OTIC a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 6.45
52 Week Low 1.5
Average Volume 169,512
200-Day Moving Average 3.1734
50-Day Moving Average 2.1802
20-Day Moving Average 1.88
10-Day Moving Average 1.964
Average True Range 0.1486
ADX 18.55
+DI 20.3625
-DI 14.7274
Chandelier Exit (Long, 3 ATRs ) 1.9242
Chandelier Exit (Short, 3 ATRs ) 1.9458
Upper Bollinger Band 2.1864
Lower Bollinger Band 1.5736
Percent B (%b) 0.74
BandWidth 32.595745
MACD Line -0.0454
MACD Signal Line -0.0865
MACD Histogram 0.0411
Fundamentals Value
Market Cap 61.51 Million
Num Shares 30.3 Million
EPS -3.45
Price-to-Earnings (P/E) Ratio -0.59
Price-to-Sales 71.13
Price-to-Book 0.61
PEG Ratio -0.05
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.19
Resistance 3 (R3) 2.20 2.16 2.16
Resistance 2 (R2) 2.16 2.12 2.16 2.15
Resistance 1 (R1) 2.10 2.10 2.13 2.08 2.14
Pivot Point 2.06 2.06 2.07 2.05 2.06
Support 1 (S1) 1.99 2.01 2.02 1.98 1.92
Support 2 (S2) 1.95 1.99 1.94 1.91
Support 3 (S3) 1.88 1.95 1.90
Support 4 (S4) 1.87